Compounds > indirubin-3'-monoxime

indirubin-3'-monoxime and n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea

indirubin-3'-monoxime has been researched along with n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Flajolet, M; Greengard, P; Meijer, L1
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Jagarlapudi, SA; Sinha, BN; Tajne, S; Vadivelan, S1
Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A1
Chen, R; Han, Y; Li, M; Li, W; Ruan, H; Wang, W; Wang, Y; Yang, Y; Ying, C; You, Y; Zhu, X1

Reviews

1 review(s) available for indirubin-3'-monoxime and n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea

ArticleYear
Pharmacological inhibitors of glycogen synthase kinase 3.
    Trends in pharmacological sciences, 2004, Volume: 25, Issue:9

    Topics: Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Humans; Neoplasms; Nervous System Diseases; Parasitic Diseases; Signal Transduction; Stem Cells; Structure-Activity Relationship

2004

Other Studies

4 other study(ies) available for indirubin-3'-monoxime and n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea

ArticleYear
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:6

    Topics: Algorithms; Computer Simulation; Databases, Factual; Drug Design; Drug Evaluation, Preclinical; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Models, Chemical; Models, Molecular; Molecular Structure; Oxazines; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Stereoisomerism; Structure-Activity Relationship

2009
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
    The Biochemical journal, 2013, Apr-15, Volume: 451, Issue:2

    Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase

2013
Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity.
    Neuropharmacology, 2007, Volume: 52, Issue:8

    Topics: Analysis of Variance; Animals; Apoptosis; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Freezing Reaction, Cataleptic; Glycogen Synthase Kinase 3; Indoles; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neurons; Oximes; tau Proteins; Thiazoles; Tyrosine 3-Monooxygenase; Urea

2007